P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?

Abstract

Authors

D. Patil E. Oehrlein

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×